Clinical-stage biopharmaceutical company VistaGen Therapeutics (NASDAQ: VTGN) recently announced that it has been issued U.S. Patent No. 9,834,801 by the U.S. Patent and Trademark Office (“USPTO”), strengthening its intellectual property (“IP”) stance. The newly-issued patent covers certain methods of production for AV-101, VistaGen’s lead central nervous system (“CNS”) product candidate. “This issued U.S. patent, in conjunction with the potential issuance of additional AV-101 patent applications currently under review worldwide, provides VistaGen with added long-term intellectual property protection for AV-101 and enhances its commercial potential,” VistaGen CEO Shawn Singh stated in the news release.
To view the full press release, visit http://dtn.fm/fo08S
About VistaGen
VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other CNS disorders. VistaGen’s lead CNS product candidate, AV-101, is in Phase 2 development, initially as a new generation oral antidepressant drug candidate for major depressive disorder (MDD). AV-101′s mechanism of action is fundamentally different from all FDA-approved antidepressants and atypical antipsychotics used adjunctively to treat MDD, with potential to drive a paradigm shift towards a new generation of safer and faster-acting antidepressants. AV-101 is currently being evaluated by the National Institute of Mental Health (NIMH) in a small Phase 2 monotherapy study in MDD being fully funded by the NIMH and conducted by Dr. Carlos Zarate Jr., Chief, Section on the Neurobiology and Treatment of Mood Disorders and Chief of Experimental Therapeutics and Pathophysiology Branch at the NIMH. VistaGen is preparing to launch a 180-patient Phase 2 study of AV-101 as an adjunctive treatment for MDD patients with an inadequate response to standard, FDA-approved antidepressants, with Dr. Maurizio Fava of Harvard University as Principal Investigator. AV-101 may also have the potential to treat multiple CNS disorders and neurodegenerative diseases in addition to MDD, including neuropathic pain, epilepsy, Huntington’s disease, Parkinson’s disease levodopa-induced dyskinesia and other disorders where modulation of the NMDA receptors, activation of the AMPA neurotransmitter pathways and/or key active metabolites of AV-101 may achieve therapeutic benefit. For more information, visit the company’s website at www.VistaGen.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Thursday, December 7, 2017
MissionIRNewsBreaks – Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF) Well Positioned in Growing Market for Lithium as Momentum Gains
Lithium mining companies such as Standard Lithium (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF) are racing to meet the surging demand for lithium while a scarce market supply forecasts an anticipated shortage by major producers. An article discussing this reads: “To exceed objectives and market expectations, Standard Lithium has established a world class Scientific Advisory Council of lithium extraction scientists and process engineers that is in charge of the lithium extraction process testing work (http://dtn.fm/un4Bn). As Standard Lithium CEO Robert Mintak stated, “Standard Lithium has a very clear focus…we have the ideal team with a blend of experience, knowledge, technical agility and pragmatic problem-solving abilities, to develop optimal process solutions for Standard Lithium’s world-class assets”. Standard Lithium is determined to produce low cost domestic lithium and capitalize on the immense global shortages.”
To view the full article, visit http://dtn.fm/PfAR7
About Standard Lithium Ltd.
Standard’s value creation strategy encompasses acquiring a diverse and highly prospective portfolio of large-scale domestic brine resources, led by an innovative and results-oriented management team with a strong focus on technical skills. The company is currently focused on the immediate exploration and development of the Bristol Dry Lake Lithium Project located in the Mojave region of San Bernardino County, California; the location has significant infrastructure in-place, with easy road and rail access, abundant electricity and water sources, and is already permitted for extensive brine extraction and processing activities. The company is also commencing resource evaluation on 33,000 acres of brine leases located in the Smackover Formation. For more information, visit http://nnw.fm/standardlithium.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
To view the full article, visit http://dtn.fm/PfAR7
About Standard Lithium Ltd.
Standard’s value creation strategy encompasses acquiring a diverse and highly prospective portfolio of large-scale domestic brine resources, led by an innovative and results-oriented management team with a strong focus on technical skills. The company is currently focused on the immediate exploration and development of the Bristol Dry Lake Lithium Project located in the Mojave region of San Bernardino County, California; the location has significant infrastructure in-place, with easy road and rail access, abundant electricity and water sources, and is already permitted for extensive brine extraction and processing activities. The company is also commencing resource evaluation on 33,000 acres of brine leases located in the Smackover Formation. For more information, visit http://nnw.fm/standardlithium.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
MissionIRNewsBreaks – Myomo, Inc. (NYSE: MYO) Underwriter Fully Exercises Over-Allotment Option in Follow-on Offering
Commercial stage medical robotics company Myomo (NYSE American: MYO) recently announced that as the sole manager and underwriter of its follow-on offering, Roth Capital Partners exercised its underwriters’ over-allotment option in full. Per the underwriter’s option, Roth purchased 626,250 shares of common stock and accompanying warrants to purchase 626,250 shares of common stock, at a combined price to the public of $2.40 per share of common stock and accompanying warrant, for gross proceeds of approximately $1.5 million. This brings the company’s public offering total to 4,801,250 shares of common stock and accompanying warrants to purchase up to an aggregate of 4,801,250 shares of common stock. Myomo received gross proceeds of approximately $11.5 million. The company intends to use the net proceeds of the offering toward debt repayment, working capital and other general corporate purposes.
To view the full press release, visit http://dtn.fm/agX0p
About Myomo
Myomo, Inc. is a commercial stage medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. For more information, visit the company’s website at www.Myomo.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
To view the full press release, visit http://dtn.fm/agX0p
About Myomo
Myomo, Inc. is a commercial stage medical robotics company that offers expanded mobility for those suffering from neurological disorders and upper limb paralysis. Myomo develops and markets the MyoPro product line. MyoPro is a powered upper limb orthosis designed to restore function to the weakened or paralyzed arms of patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. For more information, visit the company’s website at www.Myomo.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
MissionIRNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Launches Pharmaceutical Cannabinoid Pipeline Websites
India Globalization Capital (NYSE American: IGC) this morning announced the launching of two new websites (www.IGCPharma.com and www.Hyalolex.com) to detail its initiatives, development timeline and pipeline of pharmaceutical cannabinoids for use in treatment of the symptoms of Alzheimer’s disease, pain, seizures and other health-related issues. Ram Mukunda, CEO of IGC, indicated in the news release that Alzheimer’s is IGC’s initial focus on the canna-pharmaceutical front and that the company’s near-term goal is to commercialize its Alzheimer’s liquid formulation as a Complimentary and Alternative Medicine (“CAM”) and sell the product through licensed medical cannabis dispensaries in the U.S., Canada and Germany. Mukunda indicated that longer-term goals include moving IGC’s Alzheimer’s formulation through FDA registered pre-clinical and clinical trials. IGC also has six provisional patent filings for phytocannabinoid-based combination therapy for the indications of pain, medical refractory epilepsy, and cachexia. Further, in May 2017, IGC acquired exclusive rights to a University of South Florida Research Foundation filed patent entitled, “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.”
To view the full press release, visit http://dtn.fm/8c2E4
About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information, please visit www.IGCinc.us.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
To view the full press release, visit http://dtn.fm/8c2E4
About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information, please visit www.IGCinc.us.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Wednesday, December 6, 2017
MissionIRNewsBreaks – Quantum Cobalt Corp. (CSE: QBOT) (FRA: 23B) Completes First Pass Exploration on Nipissing Lorrain Mine Project
Quantum Cobalt (CSE: QBOT) (FRA: 23B) this morning said it has completed its first pass exploration program on the Nipissing Lorrain Mine Property located 26 kilometers southeast of Cobalt, Ontario. The first pass program primarily focused on the historically mined Staples vein and consisted of prospecting, mapping and sampling. A total of 28 rock samples were collected and the results are pending. “We are eagerly expecting results from the Nipissing Lorrain Mine Property, and based on those interpretations this will allow the company to continue its strategic exploration of its Cobalt assets,” Quantum Cobalt chief executive officer Greg Burns stated in the news release.
To view the full press release, visit http://dtn.fm/k3dEs
About Quantum Cobalt Corp.
Quantum Cobalt Corp. (formerly Bravura Ventures Corp.) is building one of the largest land packages in the prolific mining town of Cobalt, Ontario, Canada, with the option to acquire 100 percent of the Nipissing Lorrain Cobalt Property that includes two separate claims. The property, consisting of 29 claim units for approximately 464 hectares, is located in an historically mined area with rich deposits of cobalt, silver and nickel. The area is easily accessible by road with power and infrastructure nearby. For more information, visit the company’s website at www.QuantumCobalt.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
To view the full press release, visit http://dtn.fm/k3dEs
About Quantum Cobalt Corp.
Quantum Cobalt Corp. (formerly Bravura Ventures Corp.) is building one of the largest land packages in the prolific mining town of Cobalt, Ontario, Canada, with the option to acquire 100 percent of the Nipissing Lorrain Cobalt Property that includes two separate claims. The property, consisting of 29 claim units for approximately 464 hectares, is located in an historically mined area with rich deposits of cobalt, silver and nickel. The area is easily accessible by road with power and infrastructure nearby. For more information, visit the company’s website at www.QuantumCobalt.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Monday, December 4, 2017
MissionIRNewsBreaks – Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) Provides 2018 Strategy Update Regarding Growth Plans
Licensed Canadian cannabis cultivation company Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) this morning provided an update regarding its growth plans for 2018. The company’s incoming president and CEO Nick Dean intends to focus on meeting the expected surge in demand in the recreational cannabis sector through strategic partnerships and by increasing Emblem’s total production capacity. Dean also intends to ramp up patient acquisition in the medical cannabis market utilizing the company’s strengths and quality products. “Ultimately it’s about being relentlessly driven to deliver a strong return on investment and a solid balance sheet. We will also be mindful of strategic transactions and other opportunities to accelerate our growth objectives in Canada and international markets,” incoming president and CEO Nick Dean stated in the news release.
To view the full press release, visit http://dtn.fm/3oYUD
About Emblem
Emblem is licensed under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) to cultivate and sell medical marihuana. Emblem carries out its principal activities producing marihuana from its facilities in Paris, Ontario pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations. For more information, visit the company’s website at www.EmblemCorp.com
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
To view the full press release, visit http://dtn.fm/3oYUD
About Emblem
Emblem is licensed under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) to cultivate and sell medical marihuana. Emblem carries out its principal activities producing marihuana from its facilities in Paris, Ontario pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations. For more information, visit the company’s website at www.EmblemCorp.com
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Friday, December 1, 2017
Moxian, Inc. (NASDAQ: MOXC) Key to Success: Reading Chinese Consumer Buying Habits, Then Marketing Analytics to Business Clients
- Study: Chinese consumers want to achieve greater social status through established brands, foreign goods and luxury merchandise
- MOXC sells sophisticated data to clients on what and why Chinese consumers are buying, helping translate information into efficient and effective marketing campaigns. The company is perfectly positioned between buyers and sellers
- Research finds that, in fashion, Chinese consumers want green and face-saving products
Moxian, Inc.’s (NASDAQ: MOXC) ability to attract, read, and develop real time analytics on the shopping habits of Chinese consumers in the online-to-offline (O2O) market, then selling that research to its business clients, is a vital part of its growth strategy.
MOXC is a Shenzhen, China-based company with a platform of two paid apps: Moxian+ Business and Moxian+ User. It is an integrated O2O platform operator. Sales come from paid subscriptions to those two apps, and from other related revenue streams. By developing these two apps, MOXC serves consumers and, by reading their buying habits, a growing list of business clients that wish to retail to them. MOXC is perfectly positioned between the two.
Revenue streams include targeted mobile advertising, commissions on payment processing from its China UnionPay processing module, and selling analytics and sophisticated sales data in real time to its business clients based upon the buying patterns of customers. By using the rewards of its own Mo-Points and Mo-Coins, it creates loyalty to Moxian+ User games and its social media network. Through its UnionPay module, it also supports payments from the popular AliPay and WeChat Pay.
A study of Chinese buying habits by MarketingToChina (http://dtn.fm/z8sIs) has shown that, while Chinese consumers have embraced e-commerce and want branded luxury goods, they are unique because they are often mistrustful and feel more secure with third-party payment systems, as offered by MOXC. Social media platforms are important to them, and MOXC offers that too, with Moxian+ User’s social media network and games. There are benefits to the Chinese community’s increased use of the digital market, and MOXC can read their motivations for their Moxian+ Business clients.
An example of the kind of information of value to MOXC clients: In fashion, Chinese consumers want green products and face-saving items, according to a study by The Institute of Textiles and Clothing (http://dtn.fm/QuEo5) in Hong Kong. This reflects their desire to meet social norms in all situations. They are also well aware that some Chinese apparel makers may have in the past abused the environment through water pollution. The Chinese consumer is sophisticated and wants a good public image — and will pay for it.
For more information, visit the company’s website at www.Moxian.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Subscribe to:
Posts (Atom)